{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:01:28Z","timestamp":1785247288243,"version":"3.55.0"},"reference-count":36,"publisher":"Jaypee Brothers Medical Publishing","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,27]]},"DOI":"10.5005\/jp-journals-10018-1503","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:05:16Z","timestamp":1785243916000},"page":"56-63","source":"Crossref","is-referenced-by-count":0,"title":["Bridging the Treatment Access Gap: Janus Kinase Inhibitors as First-line Advanced Therapy for Inflammatory Bowel Disease in Resource-variable Settings"],"prefix":"10.5005","volume":"16","author":[{"given":"Rowan","family":"Bandaranaike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Tarwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2017;390(10114):2769\u20132778. DOI: 10.1016\/S0140-6736(17)32448-0.","DOI":"10.1016\/S0140-6736(17)32448-0"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"2. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021;18(1):56\u201366. DOI: 10.1038\/s41575-020-00360-x.","DOI":"10.1038\/s41575-020-00360-x"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"3. Sanat ZM, Vahedi H, Malekzadeh R, et al. Epidemiologic profile of inflammatory bowel disease in Eastern Mediterranean Region (EMRO) countries: A systematic review and meta-analysis. BMC Public Health 2024;24(1):1395. DOI: 10.1186\/s12889-024-18816-z.","DOI":"10.1186\/s12889-024-18816-z"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"4. Li CJ, Wang YK, Zhang SM, et al. Global burden of inflammatory bowel disease 1990\u20132019: A systematic examination of the disease burden and twenty-year forecast. World J Gastroenterol 2023;29(42):5751\u20135767. DOI: 10.3748\/wjg.v29.i42.5751.","DOI":"10.3748\/wjg.v29.i42.5751"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"5. Aky\u00fcz F, A\u011farg\u00fcn BF, Atu\u011f \u00d6, et al. Trends in inflammatory bowel diseases across a Eurasian crossroad: A decade of multicenter data. J Clin Gastroenterol 2025 [online ahead of print]. DOI: 10.1097\/MCG.0000000000002296.","DOI":"10.1097\/MCG.0000000000002296"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"6. Kaplan GG, Ng SC. Globalisation of inflammatory bowel disease: Perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol Hepatol 2016;1(4):307\u2013316. DOI: 10.1016\/S2468-1253(16)30077-2.","DOI":"10.1016\/S2468-1253(16)30077-2"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"7. Vulto AG, Jaquez OA. The process defines the product: What really matters in biosimilar design and production? Rheumatology (Oxford) 2017;56(suppl_4):iv14\u2013iv29. DOI: 10.1093\/rheumatology\/kex278.","DOI":"10.1093\/rheumatology\/kex278"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"8. Banerjee R, Pal P, Mak JWY, et al. Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol 2020;5(12):1076\u20131088. DOI: 10.1016\/S2468-1253(20)30299-5.","DOI":"10.1016\/S2468-1253(20)30299-5"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"9. El-Hussuna A, Hauer AC, Karakan T, et al. ECCO consensus on management of inflammatory bowel disease in low- and middle-income countries. J Crohns Colitis 2026;20(1):jjaf125. DOI: 10.1093\/ecco-jcc\/jjaf125.","DOI":"10.1093\/ecco-jcc\/jjaf125"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"10. Fern\u00e1ndez-Clotet A, Castro-Poceiro J, Pan\u00e9s J. JAK inhibition: The most promising agents in the IBD pipeline? Curr Pharm Des 2019;25(1):32\u201340. DOI: 10.2174\/1381612825666190405141410.","DOI":"10.2174\/1381612825666190405141410"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"11. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;377(5):496\u2013497. DOI: 10.1056\/NEJMc1707500.","DOI":"10.1056\/NEJMc1707500"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"12. Loftus EV Jr, Pan\u00e9s J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med 2023;388(21):1966\u20131980. DOI: 10.1056\/NEJMoa2212728.","DOI":"10.1056\/NEJMoa2212728"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"13. Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials. Lancet 2022;399(10341):2113\u20132128. DOI: 10.1016\/S0140-6736(22)00581-5.","DOI":"10.1016\/S0140-6736(22)00581-5"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"14. Singh S, Loftus EV Jr, Limketkai BN, et al. AGA Clinical Guidelines Committee. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology 2024;167(7):1307\u20131343. DOI: 10.1053\/j.gastro.2024.10.001.","DOI":"10.1053\/j.gastro.2024.10.001"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"15. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline update: Ulcerative colitis in adults. Am J Gastroenterol 2025;120(6):1187\u20131224. DOI: 10.14309\/ajg.0000000000003463.","DOI":"10.14309\/ajg.0000000000003463"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"16. Lichtenstein GR, Loftus EV Jr, Isaacs KL, et al. ACG clinical guideline: Management of Crohn's disease in adults. Am J Gastroenterol 2018;113(4):481\u2013517. DOI: 10.1038\/ajg.2018.27.","DOI":"10.1038\/ajg.2018.27"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"17. Ananthakrishnan AN, Murad MH, Scott FI, et al. Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association evidence synthesis. Gastroenterology 2024;167(7):1460\u20131482. DOI: 10.1053\/j.gastro.2024.07.046.","DOI":"10.1053\/j.gastro.2024.07.046"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"18. Prokopi\u010d M, Gilca-Blanariux G, Lietava P, et al. Barriers in inflammatory bowel disease care in Central and Eastern Europe: A region-specific analysis. Therap Adv Gastroenterol 2023;16:17562848231174290. DOI: 10.1177\/17562848231174290.","DOI":"10.1177\/17562848231174290"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"19. Burisch J, Banerjee R, Watermeyer G. Equitable access to inflammatory bowel disease care: Challenges, strategies, and future directions. J Crohns Colitis 2026;20(Suppl 2):ii11\u2013ii22. DOI: 10.1093\/ecco-jcc\/jjaf205.","DOI":"10.1093\/ecco-jcc\/jjaf205"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"20. Burr NE, Gracie DJ, Black CJ, et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: Systematic review and network meta-analysis. Gut 2022;71(10):1976\u20131987. DOI: 10.1136\/gutjnl-2021-326390.","DOI":"10.1136\/gutjnl-2021-326390"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"21. Shehab M, Alrashed F, Alsayegh A, et al. Comparative efficacy of biologics and small molecule in ulcerative colitis: A systematic review and network meta-analysis. Clin Gastroenterol Hepatol 2025;23(2):250\u2013262. DOI: 10.1016\/j.cgh.2024.07.033.","DOI":"10.1016\/j.cgh.2024.07.033"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"22. Barberio B, Gracie DJ, Black CJ, et al. Network meta-analysis: Efficacy of biological therapies and small molecules as maintenance therapy in ulcerative colitis. Aliment Pharmacol Ther 2025;62(1):4\u201321. DOI: 10.1111\/apt.70209.","DOI":"10.1111\/apt.70209"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"23. Panaccione R, Regueiro M, Lee SD, et al. Upadacitinib maintenance therapy in Crohn's disease: Final results from the randomized phase 3 U-ENDURE study. Clin Gastroenterol Hepatol 2025. DOI: 10.1016\/j.cgh.2025.07.028.","DOI":"10.1016\/j.cgh.2025.07.028"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"24. Panaccione R, Pan\u00e9s J, Peyrin-Biroulet L, et al. Long-term safety of upadacitinib in patients with inflammatory bowel disease: Integrated analysis of phase 2\/3 studies. Clin Gastroenterol Hepatol 2026. DOI: 10.1016\/j.cgh.2026.02.018.","DOI":"10.1016\/j.cgh.2026.02.018"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"25. Ahuja D, Murad MH, Ma C, et al. Comparative speed of early symptomatic remission with advanced therapies for moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis. Am J Gastroenterol 2023;118(9):1618\u20131625. DOI: 10.14309\/ajg.0000000000002263.","DOI":"10.14309\/ajg.0000000000002263"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"26. Colombel JF, Hisamatsu T, Atreya R, et al. Upadacitinib reduces Crohn's disease symptoms within the first week of induction therapy. Clin Gastroenterol Hepatol 2024;22(8):1668\u20131677. DOI: 10.1016\/j.cgh.2024.02.027.","DOI":"10.1016\/j.cgh.2024.02.027"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"27. Garc\u00eda MJ, Brenes Y, Vicu\u00f1a M, et al. Persistence, effectiveness, and safety of upadacitinib in Crohn's disease and ulcerative colitis in real life: Results from a Spanish nationwide study (UREAL study). Am J Gastroenterol 2024;120(7):1593\u20131604. DOI: 10.14309\/ajg.0000000000003243.","DOI":"10.14309\/ajg.0000000000003243"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"28. Din S, Selinger CP, Black CJ, et al. Systematic review with network meta-analysis: Risk of herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Aliment Pharmacol Ther 2023;57(6):666\u2013675. DOI: 10.1111\/apt.17379.","DOI":"10.1111\/apt.17379"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"29. Caldera F, Kane S, Long M, et al. AGA clinical practice update on noncolorectal cancer screening and vaccinations in patients with inflammatory bowel disease: Expert review. Clin Gastroenterol Hepatol 2025;23(5):695\u2013706. DOI: 10.1016\/j.cgh.2024.12.011.","DOI":"10.1016\/j.cgh.2024.12.011"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"30. Sieiro Santos C, Herrero JG, Ordas Mart\u00ednez J, et al. Differences in immunogenicity to zoster recombinant vaccine in IMID patients undergoing treatment with non-selective or selective JAK-i. Rheumatology (Oxford) 2026;65(1):keaf533. DOI: 10.1093\/rheumatology\/keaf533.","DOI":"10.1093\/rheumatology\/keaf533"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"31. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022;386(4):316\u2013326. DOI: 10.1056\/NEJMoa2109927.","DOI":"10.1056\/NEJMoa2109927"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"32. Ahuja D, Yeh KH, Patel SB, et al. Comparative safety of Janus kinase inhibitors vs. tumor necrosis factor antagonists in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2026;24(3):794\u2013804. DOI: 10.1016\/j.cgh.2025.06.041.","DOI":"10.1016\/j.cgh.2025.06.041"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"33. Alsakarneh S, Aburumman R, Khraisat F, et al. Major adverse cardiovascular events and VTE in patients with IBD taking anti-TNF versus JAK inhibitors: A multicenter cohort analysis. Dig Dis Sci 2026. DOI: 10.1007\/s10620-026-09729-5.","DOI":"10.1007\/s10620-026-09729-5"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"34. Yang H, An T, Zhao Y, et al. Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: A systematic review and network meta-analysis. Ann Med 2025;57(1):2455536. DOI: 10.1080\/07853890.2025.2455536.","DOI":"10.1080\/07853890.2025.2455536"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"35. West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med 2017;23(5):579\u2013589. DOI: 10.1038\/nm.4307.","DOI":"10.1038\/nm.4307"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"36. Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease\u2014An update. J Crohns Colitis 2017;11(1):26\u201334. DOI: 10.1093\/ecco-jcc\/jjw198.","DOI":"10.1093\/ecco-jcc\/jjw198"}],"container-title":["Euroasian journal of hepato-gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ejohg.com\/doi\/pdf\/10.5005\/jp-journals-10018-1503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:05:19Z","timestamp":1785243919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejohg.com\/doi\/10.5005\/jp-journals-10018-1503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"alternative-id":["10.5005\/jp-journals-10018-1503"],"URL":"https:\/\/doi.org\/10.5005\/jp-journals-10018-1503","relation":{},"ISSN":["2231-5047","2231-5128"],"issn-type":[{"value":"2231-5047","type":"print"},{"value":"2231-5128","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}